These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 28689432)

  • 1. Metabolite profiling in early clinical drug development: current status and future prospects.
    Ufer M; Juif PE; Boof ML; Muehlan C; Dingemanse J
    Expert Opin Drug Metab Toxicol; 2017 Aug; 13(8):803-806. PubMed ID: 28689432
    [No Abstract]   [Full Text] [Related]  

  • 2. Metabolite identification and profiling in drug design: current practice and future directions.
    Zhang Z; Zhu M; Tang W
    Curr Pharm Des; 2009; 15(19):2220-35. PubMed ID: 19601824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metabolomics in pharmaceutical research and development: metabolites, mechanisms and pathways.
    Xu EY; Schaefer WH; Xu Q
    Curr Opin Drug Discov Devel; 2009 Jan; 12(1):40-52. PubMed ID: 19152212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Addressing the challenges of low clearance in drug research.
    Di L; Obach RS
    AAPS J; 2015 Mar; 17(2):352-7. PubMed ID: 25567366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Best practices for metabolite quantification in drug development: updated recommendation from the European Bioanalysis Forum.
    Timmerman P; Blech S; White S; Green M; Delatour C; McDougall S; Mannens G; Smeraglia J; Williams S; Young G
    Bioanalysis; 2016 Jun; 8(12):1297-305. PubMed ID: 27217058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug design from the ADME/PK perspective: does chemical intuition suffice in multifaceted drug discovery?
    Lombando F; Waters NJ
    Curr Top Med Chem; 2011; 11(4):331-3. PubMed ID: 21320061
    [No Abstract]   [Full Text] [Related]  

  • 7. Applications of high-throughput ADME in drug discovery.
    Kassel DB
    Curr Opin Chem Biol; 2004 Jun; 8(3):339-45. PubMed ID: 15183334
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolomics and biochemical profiling in drug discovery and development.
    Watkins SM; German JB
    Curr Opin Mol Ther; 2002 Jun; 4(3):224-8. PubMed ID: 12139307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In silico ADME-Tox modeling: progress and prospects.
    Alqahtani S
    Expert Opin Drug Metab Toxicol; 2017 Nov; 13(11):1147-1158. PubMed ID: 28988506
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics.
    Rasmussen HB; Bjerre D; Linnet K; Jürgens G; Dalhoff K; Stefansson H; Hankemeier T; Kaddurah-Daouk R; Taboureau O; Brunak S; Houmann T; Jeppesen P; Pagsberg AK; Plessen K; Dyrborg J; Hansen PR; Hansen PE; Hughes T; Werge T;
    Pharmacogenomics; 2015; 16(6):649-65. PubMed ID: 25896426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strategic proposals for avoiding toxic interactions with drugs for clinical use during development and after marketing of a new drug: pharmacokinetic consideration.
    Sugiyama Y; Iwatsubo T; Ueda K; Ito K
    J Toxicol Sci; 1996 Dec; 21(5):309-16. PubMed ID: 9035043
    [No Abstract]   [Full Text] [Related]  

  • 12. Chirality in new drug development. Clinical pharmacokinetic considerations.
    Nation RL
    Clin Pharmacokinet; 1994 Oct; 27(4):249-55. PubMed ID: 7834962
    [No Abstract]   [Full Text] [Related]  

  • 13. [The role of ADME evaluation in translation research of innovative drug].
    Liu Y; Hong L; Yu LS; Jiang HD; Chen JZ; Meng Q; Chen SQ; Zeng S
    Yao Xue Xue Bao; 2011 Jan; 46(1):19-29. PubMed ID: 21465804
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolomics in toxicology: preclinical and clinical applications.
    Robertson DG; Watkins PB; Reily MD
    Toxicol Sci; 2011 Mar; 120 Suppl 1():S146-70. PubMed ID: 21127352
    [No Abstract]   [Full Text] [Related]  

  • 15. Cell culture metabolomics: applications and future directions.
    Cuperlović-Culf M; Barnett DA; Culf AS; Chute I
    Drug Discov Today; 2010 Aug; 15(15-16):610-21. PubMed ID: 20601091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential--toward a consensus.
    Tucker GT; Houston JB; Huang SM
    Pharm Res; 2001 Aug; 18(8):1071-80. PubMed ID: 11587475
    [No Abstract]   [Full Text] [Related]  

  • 17. Nuclear magnetic resonance (NMR)-based drug metabolite profiling.
    Lenz EM
    Methods Mol Biol; 2011; 708():299-319. PubMed ID: 21207298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The long, hard road: drug metabolism in the lifetime of the DMDG.
    Smith DA
    Xenobiotica; 2001; 31(8-9):459-67. PubMed ID: 11569522
    [No Abstract]   [Full Text] [Related]  

  • 19. Promiscuity: what protects us, perplexes us.
    Redinbo MR
    Drug Discov Today; 2004 May; 9(10):431-2. PubMed ID: 15109946
    [No Abstract]   [Full Text] [Related]  

  • 20. Integration of microfluidic LC with HRMS for the analysis of analytes in biofluids: past, present and future.
    Rainville PD; Langridge JI; Wrona MD; Wilson ID; Plumb RS
    Bioanalysis; 2015; 7(11):1397-411. PubMed ID: 26110713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.